Global Non-Oncology Precision Medicine Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Non-Oncology Precision Medicine Market Research Report 2024
In the non-oncology precision medicine market, the application of molecular biology is to study the etiology of diseases other than cancer at the molecular level, so target-based therapy or individualized therapy can be used to cure patients' health-related problems.
According to MRAResearch’s new survey, global Non-Oncology Precision Medicine market is projected to reach US$ 111430 million in 2033, increasing from US$ 83330 million in 2022, with the CAGR of 4.3% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Non-Oncology Precision Medicine market research.
Key companies engaged in the Non-Oncology Precision Medicine industry include Abbott Laboratories, Agilent Technologies, Inc., Asuragen, Inc., Almac Group, AstraZeneca PLC, Bristol Myers Squibb, bioMérieux SA., BGI and Danaher Corp., etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Non-Oncology Precision Medicine were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Non-Oncology Precision Medicine market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Non-Oncology Precision Medicine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Abbott Laboratories
Agilent Technologies, Inc.
Asuragen, Inc.
Almac Group
AstraZeneca PLC
Bristol Myers Squibb
bioMérieux SA.
BGI
Danaher Corp.
Illumina, Inc.
Invitae Corporation
Opko Health, Inc.
Teva Pharmaceutical Industries Ltd.
Segment by Type
Applied Sciences
Precision Diagnostics
Digital Health and Information Technology
Precision Therapeutics
Infectious Diseases
Neurology
Cardiovascular
Lifestyle and Endocrinology
Gastroenterology
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Non-Oncology Precision Medicine report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to MRAResearch’s new survey, global Non-Oncology Precision Medicine market is projected to reach US$ 111430 million in 2033, increasing from US$ 83330 million in 2022, with the CAGR of 4.3% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Non-Oncology Precision Medicine market research.
Key companies engaged in the Non-Oncology Precision Medicine industry include Abbott Laboratories, Agilent Technologies, Inc., Asuragen, Inc., Almac Group, AstraZeneca PLC, Bristol Myers Squibb, bioMérieux SA., BGI and Danaher Corp., etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Non-Oncology Precision Medicine were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Non-Oncology Precision Medicine market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Non-Oncology Precision Medicine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Abbott Laboratories
Agilent Technologies, Inc.
Asuragen, Inc.
Almac Group
AstraZeneca PLC
Bristol Myers Squibb
bioMérieux SA.
BGI
Danaher Corp.
Illumina, Inc.
Invitae Corporation
Opko Health, Inc.
Teva Pharmaceutical Industries Ltd.
Segment by Type
Applied Sciences
Precision Diagnostics
Digital Health and Information Technology
Precision Therapeutics
Segment by Application
Infectious Diseases
Neurology
Cardiovascular
Lifestyle and Endocrinology
Gastroenterology
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Non-Oncology Precision Medicine report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source